GLP's and Muscle Loss: What Prescribers Need to Know
GLP's therapy produces significant weight loss, but a portion of that loss can be lean muscle mass. Here is what the research shows and how prescribers can help patients preserve muscle during GLP's therapy.
GLP-1 and Muscle Loss: What Prescribers Need to Know
GLP-1 receptor agonists produce impressive weight loss results — but not all weight lost is fat. Research has consistently shown that a significant portion of weight lost during GLP-1 therapy comes from lean mass, including muscle. For prescribers, understanding this issue and having a protocol to address it is increasingly important.
The Lean Mass Loss Problem
In the STEP trials for semaglutide, approximately 39% of total weight lost was lean mass. In the SURMOUNT trials for tirzepatide, the proportion was similar — roughly 25–40% of total weight loss was lean mass, depending on the trial and the analysis.
For a patient who loses 50 pounds on GLP-1 therapy, this means 12–20 pounds of that loss may be muscle, not fat. This has significant implications:
Functional consequences: Muscle loss reduces strength, functional capacity, and quality of life — particularly in older patients.
Metabolic consequences: Muscle is metabolically active tissue. Losing muscle reduces resting metabolic rate, which can make weight maintenance harder after GLP-1 therapy is discontinued.
Bone health: Lean mass loss is associated with reduced bone density, increasing fracture risk.
Sarcopenic obesity: Patients who lose muscle while retaining fat (or who regain fat after stopping GLP-1 therapy) can end up with sarcopenic obesity — a particularly unfavorable body composition.
Why GLP-1 Therapy Causes Muscle Loss
The mechanism of lean mass loss during GLP-1 therapy is not fully understood, but several factors contribute:
Caloric deficit: GLP-1 agents reduce appetite and caloric intake. Any significant caloric deficit will result in some lean mass loss, regardless of the mechanism.
Reduced protein intake: Patients on GLP-1 therapy often eat less protein because they eat less overall. Inadequate protein intake accelerates muscle loss.
Reduced physical activity: Some patients on GLP-1 therapy reduce physical activity due to fatigue or GI side effects, which reduces the anabolic stimulus for muscle maintenance.
Possible direct effects: Some research suggests GLP-1 receptors may be expressed in muscle tissue, and GLP-1 agonism may have direct effects on muscle metabolism — though this is not fully established.
Strategies to Preserve Lean Mass
1. Adequate Protein Intake
Protein is the most important nutritional factor for lean mass preservation during weight loss. Current evidence supports:
- Minimum: 1.2 g/kg of body weight per day
- Optimal: 1.6–2.0 g/kg of body weight per day for patients on GLP-1 therapy
- Distribution: Spread protein intake across meals (30–40 g per meal) rather than concentrating it in one meal
Patients on GLP-1 therapy often struggle to meet protein targets because their appetite is suppressed. Protein shakes and high-protein foods (Greek yogurt, cottage cheese, eggs, lean meats) can help.
2. Resistance Training
Resistance exercise is the most effective intervention for preserving and building lean mass. Prescribers should:
- Recommend resistance training at least 2–3 times per week
- Emphasize that resistance training is more important than cardio for lean mass preservation
- Consider referring patients to a physical therapist or certified personal trainer
3. Leucine and Essential Amino Acids
Leucine is the key amino acid that triggers muscle protein synthesis. Supplementation with leucine or essential amino acids (EAAs) can support lean mass preservation, particularly in patients who struggle to meet protein targets through food.
4. Creatine Supplementation
Creatine monohydrate is one of the most well-studied supplements for lean mass preservation. A 2024 meta-analysis found that creatine supplementation during caloric restriction reduced lean mass loss by approximately 1.5 kg compared to placebo. Dose: 3–5 g/day.
5. Monitoring Body Composition
Standard weight measurements do not distinguish between fat and lean mass loss. Consider using:
- DEXA scan (gold standard for body composition)
- Bioelectrical impedance analysis (BIA) — less accurate but more accessible
- Anthropometric measurements (waist circumference, body fat percentage)
Monitoring body composition allows you to identify patients who are losing disproportionate lean mass and adjust their protocol.
The Role of Peptides in Lean Mass Preservation
Some practices are exploring the use of peptides alongside GLP-1 therapy to support lean mass preservation. Compounds of interest include:
BPC-157: Studied for tissue repair and recovery. Available as an RUO peptide.
CJC-1295/Ipamorelin: Growth hormone secretagogues studied for effects on body composition. Available as RUO peptides.
These compounds are available through our RUO catalog for research purposes. They are not FDA-approved for therapeutic use.
Patient Communication
Patients should be counseled about lean mass loss before starting GLP-1 therapy:
- Weight loss will include some lean mass — this is normal and expected
- Protein intake and resistance training are essential to minimize lean mass loss
- Body composition monitoring can help track progress
- The goal is fat loss, not just weight loss
This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should use clinical judgment when developing patient protocols.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
